Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

DENTSPLY (XRAY) Q3 Earnings: Is Disappointment In Store?

Published 11/02/2016, 06:02 AM
Updated 07/09/2023, 06:31 AM

DENTSPLY Sirona Inc. (NASDAQ:XRAY) is expected to report third-quarter 2016 results on Nov 4. Last quarter, the company reported earnings of 76 cents per share, which beat the Zacks Consensus Estimate by 6 cents.

Notably, the company’s results compared favorably with the Zacks Consensus Estimate in the last four quarters, with an average beat of 5.71%.

Let's see how things are shaping up for this quarter.

Factors at Play

We believe the DENTSPLY-Sirona combined entity will benefit from revenue and cost synergies in 2016 and beyond. Moreover, a gradual recovery in the U.S. market should benefit DENTSPLY. Also, emerging markets provide significant opportunities for the company as these areas are vastly untapped with low dental products’ penetration.

However, integration will be a risk in the near term. Moreover, unfavorable foreign exchange rate volatility will continue to hurt DENTSPLY’s results in the immediate future. Additionally, higher capital expenditure on product development, along with persistent decline in sales, is expected to keep margins under pressure.

Overall, the company’s activities during the July–September period were inadequate to win analysts’ confidence. As a result, the Zacks Consensus Estimate for the third quarter deteriorated to 63 cents from 68 cents per share over the last 90 days.

DENTSPLY SIRONA Price and EPS Surprise

DENTSPLY SIRONA Price and EPS Surprise | DENTSPLY SIRONA Quote

Earnings Whispers

Our proven model does not conclusively show that DENTSPLY is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.

Zacks ESP: The Earnings ESP for DENTSPLY is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 70 cents. Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.

Zacks Rank: DENTSPLY carries a Zacks Rank #4, which decreases the predictive power of ESP. We caution against stocks with a Zacks Ranks #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Stocks to Consider

Here are a few stocks worth considering that, per our model, have the right combination of elements to post an earnings beat this quarter:

Glaukos Corporation (NYSE:GKOS) has an Earnings ESP of +100% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Bard C R Inc. (NYSE:BCR) has an Earnings ESP of +0.37% and a Zacks Rank #2.

Invuity, Inc. (NASDAQ:IVTY) has an Earnings ESP of +1.61% and a Zacks Rank #2.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



BARD C R INC (BCR): Free Stock Analysis Report

DENTSPLY SIRONA (XRAY): Free Stock Analysis Report

GLAUKOS CORP (GKOS): Free Stock Analysis Report

INVUITY INC (IVTY): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.